MorphoSys was founded in Martinsried near Munich in 1992. The founders included Dr. Simon Moroney, today’s CEO of the Company and Prof. Dr. Andreas Plückthun. Today, MorphoSys is one of the world’s leading biotechnology companies in the area of fully human antibodies.













Company founded in Martinsried/Munich, Germany






First commercial partnership with Pharmacia-Upjohn

Move to the Innovation and Start-up Center for Biotechnology (IZB) Martinsried








IPO at the Frankfurt Stock Exchange

Start of an extensive partnership with Bayer AG


Patent dispute begins with Cambridge Antibody Technology









Presentation of the HuCAL antibody library

First HuCAL patent granted








Presentation of the HuCAL GOLD antibody library

Start of a strategic partnership with Schering AG








MorphoSys achieves a settlement of the CAT patent dispute

Dr. Simon E. Moroney receives the Bundesverdienstkreuz am Bande (Cross of the Order of Merit of the Federal Republic of Germany)








Start of a partnership with Pfizer

HuCAL antibodies to combat Alzheimer’s produce positive preclinical results








Start of a strategic partnership with Novartis

Presentation of the new research antibodies division, Antibodies by Design


Inclusion in the technology index TecDAX


MorphoSys achieves break even










The first HuCAL antibodies used in clinics

Acquisition of Biogenesis Group strengthens the research segment


First partnership with a Japanese pharmaceutical group









Acquisition of Serotec Group further strengthens the research segment

HuCAL antibodies to combat Alzheimer’s disease are used in clinics








MorphoSys announces development of new antibody platform technology

MorphoSys and Novartis forge one of the industry’s largest pharma-biotech R&D collaborations








First proprietary therapeutic antibody MOR103 enters clinical trials

MorphoSys unveils new antibody library, HuCAL PLATINUM


First HuCAL antibody enters phase 2 clinical trials









MorphoSys signs first infectious disease alliance with Daiichi-Sankyo




First proprietary therapeutic antibody in a patient setting

First in-licensing of a clinical antibody from Xencor


Aquisition of Sloning BioTechnology


MorphoSys presents new antibody technology arYla








MOR202 enters clinical development

MorphoSys presents new antibody technology Ylanthia


MorphoSys signs first industrial biotechnology alliance with Novozymes




MorphoSys announces positive clinical data for MOR103 in RA and MOR208 in CLL

With gantenerumab from Roche, the first partnered antibody program reaches late stage development

MorphoSys celebrates its 20th anniversary

MorphoSys signs first Ylanthia-based therapeutic partnership


MorphoSys completes sale of AbD Serotec to Bio-Rad

MorphoSys signs license agreement with GlaxoSmithKline for MOR103 program

MorphoSys signs strategic alliance with Celgene for MOR202 program

MorphoSys collaborator Novartis starts pivotal study with bimagrumab


MorphoSys and Merck Serono enter strategic immuno-oncology collaboration

MorphoSys and Emergent BioSolutions sign license agreement to co-develop and commercialize prostate cancer drug candidate MOR209/ES414


Product Pipeline

The pipeline is increasingly taking center stage.